Free Trial

Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.67

Lexicon Pharmaceuticals logo with Medical background

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned a consensus rating of "Hold" from the five ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.67.

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. Piper Sandler lowered their target price on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners reissued a "market perform" rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Wall Street Zen assumed coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating on the stock.

Get Our Latest Report on LXRX

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Arizona State Retirement System boosted its stake in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 16,136 shares in the last quarter. Swiss National Bank boosted its stake in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company's stock worth $315,000 after purchasing an additional 109,100 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 24,615 shares in the last quarter. Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $66,000. Finally, Wellington Management Group LLP lifted its stake in Lexicon Pharmaceuticals by 2.1% during the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after acquiring an additional 15,249 shares during the period. Hedge funds and other institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX traded up $0.02 during midday trading on Friday, reaching $0.75. The stock had a trading volume of 3,608,490 shares, compared to its average volume of 6,691,290. The stock has a 50-day moving average of $0.64 and a 200-day moving average of $0.65. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.22. The company has a market capitalization of $269.49 million, a price-to-earnings ratio of -1.46 and a beta of 1.00. Lexicon Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative return on equity of 103.16%. The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. As a group, research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

About Lexicon Pharmaceuticals

(Get Free Report

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

Further Reading

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Should You Invest $1,000 in Lexicon Pharmaceuticals Right Now?

Before you consider Lexicon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.

While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines